A study conducted by Kim et al. found compound EGFR mutations in 24.6% of the cases of EGFR-mutant lung adenocarcinoma, and the majority of them were represented by a combination of the atypical mutation and typical mutation. This evidence concerns the gene EGFR and lung adenocarcinoma.